<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00083005</url>
  </required_header>
  <id_info>
    <org_study_id>040132</org_study_id>
    <secondary_id>04-C-0132</secondary_id>
    <secondary_id>CDR0000361758</secondary_id>
    <nct_id>NCT00083005</nct_id>
    <nct_alias>NCT00078650</nct_alias>
  </id_info>
  <brief_title>Docetaxel, Estramustine, and Thalidomide in Treating Patients With Androgen-Independent Metastatic Adenocarcinoma of the Prostate</brief_title>
  <official_title>A Phase II Trial Combining Estramustine, Docetaxel And Thalidomide In Patients With Androgen-Independent Metastatic Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institutes of Health Clinical Center (CC)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as docetaxel and estramustine, work in different&#xD;
      ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the&#xD;
      growth of prostate cancer by stopping blood flow to the tumor. Giving chemotherapy together&#xD;
      with thalidomide may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving docetaxel and estramustine together&#xD;
      with thalidomide works in treating patients with androgen-independent metastatic&#xD;
      adenocarcinoma (cancer) of the prostate.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the prostate-specific antigen response in patients with androgen-independent&#xD;
           metastatic adenocarcinoma of the prostate treated with docetaxel, estramustine, and&#xD;
           thalidomide.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the survival duration in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the pharmacokinetics of both docetaxel and thalidomide in patients treated&#xD;
           with this regimen.&#xD;
&#xD;
        -  Determine whether any pharmacodynamic relationships exist between plasma concentrations&#xD;
           of docetaxel and/or thalidomide and clinical activity or toxicity of this regimen in&#xD;
           these patients.&#xD;
&#xD;
        -  Determine the existence of and quantification of circulating prostate cancer cells in&#xD;
           patients before and after treatment with this regimen.&#xD;
&#xD;
        -  Determine genotype, with regard to cytochrome P450 2C19 polymorphism, in patients&#xD;
           treated with this regimen.&#xD;
&#xD;
        -  Correlate genotype with pharmacokinetics and efficacy of this regimen in these patients.&#xD;
&#xD;
        -  Determine the changes in molecular markers of angiogenesis (including, but not limited&#xD;
           to, serum and urine vascular endothelial growth factor) in patients before and after&#xD;
           treatment with this regimen.&#xD;
&#xD;
        -  Determine the toxicity profile of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label study.&#xD;
&#xD;
      Patients receive docetaxel IV over 30 minutes on days 2, 9, and 16, oral thalidomide once&#xD;
      daily on days 1-28, and oral estramustine three times daily on days 1-3, 8-10, and 15-17.&#xD;
      Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed for survival.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 33-60 patients will be accrued for this study within 11-20&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PSA response</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>estramustine phosphate sodium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thalidomide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
               -  Metastatic disease&#xD;
&#xD;
               -  Androgen-independent disease&#xD;
&#xD;
          -  Clinically progressive disease documented by at least 1 of the following parameters:&#xD;
&#xD;
               -  Two consecutively rising prostate-specific antigen (PSA) levels taken at least 1&#xD;
                  week apart&#xD;
&#xD;
                    -  PSA ≥ 5.0 ng/mL&#xD;
&#xD;
                    -  Continued rise in PSA 4 weeks after discontinuation of prior flutamide OR 6&#xD;
                       weeks after discontinuation of prior bicalutamide or nilutamide (for&#xD;
                       patients treated with anti-androgen agents)&#xD;
&#xD;
               -  At least 1 new lesion on bone scan&#xD;
&#xD;
               -  Progressive measurable disease&#xD;
&#xD;
          -  Must have undergone bilateral surgical castration OR continue on a&#xD;
             gonadotropin-releasing hormone agonist&#xD;
&#xD;
          -  No brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3*&#xD;
&#xD;
          -  Hemoglobin ≥ 7.5 g/dL* NOTE: *No transfusions within the past 2 weeks&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST and ALT &lt; 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin &lt; ULN (≤ 3.0 times ULN for patients with Gilbert's syndrome)&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.5 times ULN OR&#xD;
&#xD;
          -  Fractionated hepatic alkaline phosphatase ≤ 2.5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance ≥ 40 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No transient ischemic attacks or cerebrovascular accident within the past 2 years&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No uncontrolled congestive heart failure&#xD;
&#xD;
          -  No uncontrolled angina pectoris&#xD;
&#xD;
          -  No thromboembolic disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No peripheral neuropathy ≥ grade 2&#xD;
&#xD;
          -  No cognitive impairment that would preclude study participation or giving informed&#xD;
             consent&#xD;
&#xD;
          -  No other active malignancy within the past 2 years except non-melanoma skin cancer or&#xD;
             superficial bladder carcinoma&#xD;
&#xD;
          -  Fertile patients must use effective contraception for at least 1 month before, during,&#xD;
             and for at least 1 month after study treatment&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No prior thalidomide&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior docetaxel&#xD;
&#xD;
          -  No prior estramustine&#xD;
&#xD;
          -  No prior chemotherapy for metastatic prostate cancer&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Recovered from prior radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from prior surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No concurrent antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No concurrent complementary or alternative therapy that would interact with study&#xD;
             drugs&#xD;
&#xD;
          -  No concurrent herbal or nutritional products or dietary supplements that would&#xD;
             interact with study drugs&#xD;
&#xD;
          -  No concurrent aprepitant as secondary prophylaxis or antiemetic treatment&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Avi S. Retter, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Eastchester Center for Cancer Care</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NCI - Center for Cancer Research</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Sissung TM, Danesi R, Kirkland CT, Baum CE, Ockers SB, Stein EV, Venzon D, Price DK, Figg WD. Estrogen receptor α and aromatase polymorphisms affect risk, prognosis, and therapeutic outcome in men with castration-resistant prostate cancer treated with docetaxel-based therapy. J Clin Endocrinol Metab. 2011 Feb;96(2):E368-72. doi: 10.1210/jc.2010-2070. Epub 2010 Nov 24.</citation>
    <PMID>21106711</PMID>
  </reference>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>May 14, 2004</study_first_submitted>
  <study_first_submitted_qc>May 14, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2004</study_first_posted>
  <last_update_submitted>March 14, 2012</last_update_submitted>
  <last_update_submitted_qc>March 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2012</last_update_posted>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Estramustine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

